Recall events
/
Event 98136
Event summary
Timeline bucket December 16, 2025
Product types Drug
Classifications Class II
Statuses Ongoing
Recalling firm wording SpecGx, LLC
Dossier provenance
Source snapshots represented here
openFDA Drug Enforcement
Report-date coverage
June 20, 2012–July 08, 2026
Known gap: openFDA describes 2004-present coverage, but the current export has no report-date records in this interval.
Enforcement coverage uses report dates; product initiation dates can precede those bounds. Device-enrichment coverage uses FDA event_date_initiated.
How coverage and grouping work
Device root-cause evidence is not applicable to this event.
No grouped product has the official product type device; this is not an unavailable-enrichment finding.
Complete imported group
Every recalled product in this event
2 official enforcement rows
Product dates, classifications, firms, and source wording remain attached to their individual rows.
Opening this dossier never hides products that did not match a prior timeline filter.
drug · product 1 of 2
Oxycodone and Acetaminophen CII Tablets USP, 10mg/325 mg, 100 tablets, Rx only, SpecGx LLC, Webster Groves, MO 63119, NDC 0406-0523-01.
D-0254-2026
Recall number D-0254-2026
Initiated December 16, 2025
Classification Class II
Status Ongoing
Quantity 287,988 Bottles.
App-derived interpretation
Unknown
reason.no_named_rule · v1.0.0
Failed Tablet/Capsule Specification: There is a potential for the imprint to be missing on tablets.
These labels are deterministic app interpretations, not FDA categories.
Inspect official wording and provenance
Reason for recall Failed Tablet/Capsule Specification: There is a potential for the imprint to be missing on tablets.
Code information Lot: 0523J23904, expires: 05/2027; 0523J24426, 0523J24427, expires: 06/2027.
Distribution pattern Nationwide
Official fact provenance
Dataset openFDA Drug Enforcement
Snapshot published July 16, 2026 07:03
Snapshot SHA-256 b791303a96cde04f35218bb062dc99bbd2aaedb7873ee857564b5dbe373c2651
Raw source locator 0001-drug-enforcement-0001-of-0001.json.zip#results[17687]
FDA event record
· Exact recall-number query on openFDA
drug · product 2 of 2
Oxycodone and Acetaminophen CII Tablets USP, 7.5 mg/325 mg, 100 tablets, Rx only, SpecGx LLC, Webster Groves, MO 63119, NDC 0406-0522-01. Case label: SpecGx LLC, NDC 0406052201, Exp. 2027/03, Lot: 0522J23493
D-0255-2026
Recall number D-0255-2026
Initiated December 16, 2025
Classification Class II
Status Ongoing
Quantity 74,544 bottles
App-derived interpretation
Unknown
reason.no_named_rule · v1.0.0
Failed Tablet/Capsule Specification: There is a potential for the imprint to be missing on tablets.
These labels are deterministic app interpretations, not FDA categories.
Inspect official wording and provenance
Reason for recall Failed Tablet/Capsule Specification: There is a potential for the imprint to be missing on tablets.
Code information Lot: 0522J23493, expires: 03/2027.
Distribution pattern Nationwide
Official fact provenance
Dataset openFDA Drug Enforcement
Snapshot published July 16, 2026 07:03
Snapshot SHA-256 b791303a96cde04f35218bb062dc99bbd2aaedb7873ee857564b5dbe373c2651
Raw source locator 0001-drug-enforcement-0001-of-0001.json.zip#results[17745]
FDA event record
· Exact recall-number query on openFDA